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AMP-activated protein kinase (AMPK) is responsible for sensing of the cell’s energetic status and it phos-
phorylates numerous substrates involved in anabolic and catabolic processes as well as interacting with
signaling cascades. Mutations in the gene encoding the c2 regulatory subunit have been shown to cause
hypertrophic cardiomyopathy (HCM) with conduction abnormalities. As part of a study to examine the
role of AMPK in the heart, we tested whether speciﬁc domains of the thick ﬁlament component cardiac
myosin binding protein-C (cMyBP-C) were good in vitro AMPK substrates. The commercially available
pET28a expression vector was used to generate a recombinant form of the cMyBP-C C8 domain as a
fusion protein with a hexahistidine tag. In vitro phosphorylation with activated kinase showed that the
puriﬁed fusion protein was a good AMPK substrate, phosphorylated at a similar rate to the control SAMS
peptide and with phosphate incorporation speciﬁcally in serine residues. However, subsequent analysis
of alanine replacement mutants and thrombin digestion revealed that the strong AMPK phosphorylation
site was contained within the thrombin cleavage sequence encoded by the vector. As this sequence is
common to many commercial pET vectors, caution is advised in the mapping of AMPK phosphorylation
sites when this sequence is present.
 2009 Elsevier Inc. Open access under CC BY-NC-ND license. AMP-activated protein kinase (AMPK)1 is an enzyme found in
all mammalian cells and is responsible for sensing energetic status.
It is activated by 50-AMP and phosphorylation, and itself phosphor-
ylates numerous substrates involved in anabolic and catabolic pro-
cesses as well as interacting with signaling cascades [1,2]. It is a
trimer composed of a catalytic a subunit, a b subunit that includes
a glycogen-binding domain and a c subunit that binds adenine
nucleotides via two pairs of cystathione b synthase (CBS) domains.
Mutations in the c2 isoform have been shown to cause hypertro-
phic cardiomyopathy (HCM) with conduction abnormalities [3].
In order to investigate the precise role of AMPK in the heart, we
have performed yeast two-hybrid screenings of human heart cDNA
libraries using AMPK subunits as bait. A screen using the short
splice variant of the c2 isoform [4,5] as bait identiﬁed the C-termi-
nal domains of cardiac myosin binding protein-C (cMyBP-C) as a
putative interactor. This protein is a component of thick myoﬁla-
ments of cardiac muscle and is postulated to play a role in the reg-
ulation of cardiac muscle contractility [6]. It is a modular protein
composed of 11 domains (termed C0–C10), eight of which areood).
kinase; CBS, cystathione b
P-C, cardiac myosin binding
Y-NC-ND license. IgI-like, the other three being ﬁbronectin three-like, and mutations
in the gene encoding cMyBP-C are a common cause of HCM [7].
This report describes the use of the commercially available
pET28a expression vector to generate recombinant cMyBP-C C8
domain as a fusion protein with a hexahistidine tag. In vitro phos-
phorylation of the fusion protein with puriﬁed activated kinase
suggested that this domain was a good AMPK substrate. However,
subsequent analysis revealed that the strong AMPK phosphoryla-
tion site is contained within the thrombin cleavage sequence en-
coded by the vector.Materials and methods
Cloning and protein production
DNAencoding theC8domainof cMyBP-C (aminoacids 975–1066)
was ampliﬁed by PCR and cloned into the bacterial expression vector
pET28a (Novagen, Fig. 1) using NdeI and HindIII. Alanine replace-
ment mutants of serines within the C8 sequence were generated by
our standard two-step PCR mutagenesis protocol using complemen-
tary primers. Plasmid DNAwas puriﬁed according to standard proce-
dures and the sequence of the pET28a-C8 constructs veriﬁed.
pET28a-C8 DNA was used to transform BL21(DE3)pLysS Esche-
richia coli and his6-C8 protein was overexpressed in cultures of
Fig. 1. Partial sequence of pET28a showing the translation start site, hexahistidine tag and thrombin recognition site. The serines encoded within the leader peptide are




Fig. 2. Phosphorylation of his6-C8 by AMPK. (A) One microgram of his6-C8 was
phosphorylated by AMPK in the presence of c32P-ATP as described in Materials and
methods and separated by SDS–PAGE. Lane 1: Coomassie Blue-stained gel; lane 2:
autoradiograph. (B) Time course of AMPK phosphorylation of 800 pmol SAMS (ﬁlled
circles) and 800 pmol his6-C8 (open circles). Phosphorylation reactions were set up
as described; aliquots were taken at the indicated time points and spotted onto
phosphocellulose paper. The radioactivity remaining on the paper after washing
with 10% TCA was determined by scintillation counting. (C) Phosphoamino acid
analysis of 32P-labeled his6-C8. Total amino acids were separated by electrophoresis
at pH 1.9 (ﬁrst) and pH 3.5 and 32P-amino acids detected by autoradiography.
Position of stained phosphoamino acid standards are marked.
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and 25 lg/ml chloramphenicol at 37 C. Expression was induced by
the addition of isopropyl b-D-1-thiogalactopyranoside to 0.4 mM
after which the cultures were grown for a further 3 h; cells were
harvested by centrifugation and the cell pellets frozen at 80 C.
For puriﬁcation, cell pellets were thawed, resuspended in 50 mM
sodium phosphate pH 8.0, 300 mMNaCl, 10 mM imidazole and cell
lysis brought about by sonication. Cell debris was removed by
centrifugation (20,000 g for 20 min at 4 C) and his6-C8 protein
isolated from the lysis supernatant using Ni2+–NTA (Qiagen) afﬁn-
ity chromatography according to the manufacturer’s instructions
(Fig. 2A). Digestion of his6-C8 fusion protein with thrombin (1 U/
lg protein) was carried out at 4 C overnight in 20 mM Tris–HCl
pH 8.4, 150 mM NaCl, 2.5 mM CaCl2.
Phosphorylation studies
Phosphorylation reactions were carried out at 37 C for 1 h with
0.37 MBq c32P-ATP in 50 mM HEPES pH 7.4, 150 mM KCl, 25 mm
MgCl2, 1 mMdithiothreitol, 125 lMAMP, 1 mMATP in the presence
of activated recombinanta1b1c1 AMPK trimer [8]. Phosphorylation
was analyzedbySDS–PAGEandautoradiographyor by spottingonto
phosphocellulose paper and scintillation counting [9].
Phosphoamino acid analysis was carried out according to a stan-
dard protocol [10]. Brieﬂy, 32P-labeled protein prepared as de-
scribed above was precipitated with 20% trichloroacetic acid
(TCA) and hydrolyzed in 5.7 M HCl at 100 C for 30 min. After re-
moval of HCl by evaporation, the amino acids were resuspended
in pH 1.9 electrophoresis buffer with phosphoserine, phosphothre-
onine and phosphotyrosine standards. The mixture was then sepa-
rated by electrophoresis on a cellulose plate in two dimensions, ﬁrst
at pH 1.9 and then at pH 3.5. Phosphoamino acid standards were
visualized by ninhydrin staining and 32P-labeled amino acids by
autoradiography.
Results
Our unpublished yeast two-hybrid data indicated a putative
interaction between the a1 subunit isoform of AMPK and domains
8–10 of cMyBP-C, thus implying that this region of cMyBP-C may
also be a substrate for this kinase. To test the latter, we used re-
combinant C8 domain (amino acids 975–1066) produced as a
hexahistidine fusion protein using the vector pET28a (Fig. 1). Incu-
bation of his6-C8 with activated AMPK resulted in incorporation of
phosphate into the recombinant protein (Fig. 2A). Furthermore, a
time course suggested that his6-C8 was a strong AMPK substrate
with a rate of phosphate incorporation similar to the model SAMS
peptide substrate (Fig. 2B). Analysis of the phosphoamino acid con-
tent of 32P-labeled his6-C8 by acid hydrolysis and two-dimensional
thin layer chromatography revealed that the phosphate was exclu-
sively incorporated into serine residue(s) (Fig. 2C).
The above data led us to suppose that the C8 domain of cMyBP-
C is a good in vitro AMPK substrate and phosphorylated on one or
more serine residues. There are three serines within the domain
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Fig. 3. Thrombin digestion reveals that the phosphorylatable serine of his6-C8 lies in the leader peptide not within C8 itself. (A and B) Thrombin digestion of AMPK-
phosphorylated his6-C8. A: Coomassie Blue-stained gel; B: autoradiograph. Lane 1: undigested AMPK-phosphorylated his6-C8 (control); lane 2: AMPK-phosphorylated his6-
C8 after thrombin digestion. (C and D) AMPK phosphorylation subsequent to thrombin digestion of his6-C8 fusion protein. A: Coomassie Blue-stained gel; B: autoradiograph.
Lane 1: undigested AMPK-phosphorylated his6-C8 (control); lane 2: AMPK-phosphorylated his6-C8 after thrombin digestion.
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mutants were generated using the parent pET28a construct to
determine which were the phosphorylatable residues. Two single
alanine replacement mutants (Ser1020Ala and Ser1040Ala), a dou-
ble (Ser1020Ala/Ser1024Ala) and a mutant with all three serine
residues replaced (Ser1020Ala/Ser1024Ala/Ser1040Ala) were engi-
neered and the recombinant proteins overexpressed and puriﬁed
as wild type. However, each alanine replacement mutant was
phosphorylated to a similar level as wild type his6-C8 (data not
shown). This surprising ﬁnding led us to examine the possibility
that a phosphorylatable serine lies within the N-terminal amino
acids encoded by the pET28a plasmid DNA; inspection of the se-
quence revealed that there are ﬁve serines in this short sequence,
a pair either side of the hexahistidine tag and one at the C-terminal
end of the six-residue thrombin recognition sequence (Fig. 1). To
test this, phosphorylated his6-C8 was digested with thrombin
(Fig. 3A and B) and also thrombin-cleaved his6-C8 phosphorylated
with AMPK (Fig. 3C and D). In contrast with thrombin treatment of
unphosphorylated his6-C8 (Fig. 3C), digestion of phosphorylated
his6-C8 was found to be incomplete as full length fusion protein
(estimated 21% of total by scanning densitometry) was present
along with a doublet produced by protease action (Fig. 3A). Auto-
radiography revealed that in the thrombin-treated sample, only
full length fusion protein, not the doublet, was phosphorylated
(Fig. 3B). This suggested that the phosphorylation is not within
the C8 domain itself; this was supported by the ﬁnding that the
doublet produced by thrombin digestion prior to AMPK phosphor-
ylation was a very poor AMPK substrate compared to intact his6-C8
(Fig. 3D). Taken together, these data strongly suggest that the prin-
cipal serine within his6-C8 that was phosphorylated in this study is
that present within the thrombin recognition site. Phosphorylation
at this residue clearly inhibits thrombin digestion (Fig. 3A and B).
As this serine is C-terminal to the site of thrombin cleavage, it is
present as the second of the four amino acids fused to C8 after
digestion to remove the hexahistidine sequence (Fig. 1); however,
with only one ﬂanking N-terminal residue, the serine is no longer a
good substrate for AMPK (Fig. 3D).
Conclusions
This study aimed to test whether the IgI-like C8 domain of
cMyBP-C is an in vitro substrate of AMPK. We used the com-
monly employed approach of producing the protein of interest
fused to a hexahistidine tag to facilitate puriﬁcation. The fusion
protein was readily puriﬁed using Ni2+–NTA afﬁnity chromatog-
raphy and was shown to be efﬁciently phosphorylated by AMPK
in vitro. However, further study showed that the phosphorylata-ble serine was present within the thrombin recognition sequence
encoded by the vector and not within C8 itself. The primary rec-
ognition sequence for AMPK is known to be very broad and has
been proposed to be /(X,basic)XXSer/ThrXXX/ where / is a
hydrophobic residue (met, val, leu, ile or phe) [11–13]. Clearly
there are many protein sequences matching these criteria that
are not AMPK phosphorylation sites, suggesting that the nature
of the local secondary structure may play an important role in
recognition and that successful prediction of strong AMPK sites
is difﬁcult. This is illustrated by the divergence from the notional
consensus sequence on known phosphorylation sites, for exam-
ple ser1200 of rat acetyl-coA carboxylase [11]. The sequence sur-
rounding the site identiﬁed here also does not ﬁt with the
proposed sequence.
The presence of the strong AMPK site within the vector-en-
coded residues proved a confounding factor in this study and we
urge caution in the use of fusion proteins containing the thrombin
recognition site in the work aimed at identifying AMPK substrates.
As this sequence occurs in many commercial pET vector series (for
example, pETs 14, 15, 41, 42, 43, 47, 48, 49, 50 and 52 as well as 28)
we hope our observation will prove useful in other laboratories’
experimental design.References
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